直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

Bill Proposes Changes to PTAB Claim Construction, CBM Practice, and Estoppel Provisions

October 28, 2013

Authored and Edited by Jeffrey C. Totten

On October 23, Congressman Bob Goodlatte (R. Virginia) introduced a bill that would alter aspects of practicing before the Patent Trial and Appeal Board. The bill, entitled “Innovation Act”, makes patent-law changes intended to curb “abusive patent litigation.” The bill includes five notable changes to IPR, PGR, and CBM practice.

First, the bill requires the Board to construe patent claims “as such claim would be in a civil action to invalidate a patent under section 282(b),” in “accordance with the ordinary and customary meaning of such claim as understood by one of ordinary skill in the art and the prosecution history pertaining to the patent.” These changes would abandon the “broadest reasonable interpretation” currently applied by the Board to IPRs, PGRs, and CBMs. Additionally, the bill requires the Board to consider claim constructions adopted in related district-court litigations.

Second, the bill adopts the definition of “covered business method” the Board applied in SAP America v. Versata. When instituting the SAP CBM, the Board noted that “financial product or service” should “be broadly interpreted” to encompass “patents claiming activates that are financial in nature, incidental to a financial activity or complementary to a financial activity.” Thus, no literal recitation of “financial products or services” is necessary to trigger CBM status. Rep. Goodlatte’s bill applies that reasoning to future CBM proceedings.

Third, the bill expands the printed prior art available in CBM proceedings. Under the bill, petitioners can seek to invalidate CBM patents under (pre-AIA) Sections 102(d), and 102(e), which were previously unavailable.

Fourth, the bill repeals the sunset provision that would otherwise phase out CBM proceedings in September of 2020. CBM proceedings would, however, remain available only for patents filed before the AIA’s first-to-file provisions took effect.

Fifth, the bill adjusts the estoppel applied to PGR proceedings, striking the phrase “or reasonably could have raised” from Section 325(e)(2). This change brings the scope of estoppel for PGRs in line with the estoppel currently applied to CBMs, meaning that parties are only bound by grounds they actually raise. The bill leaves the estoppel provision for IPRs unchanged.

Tags

broadest reasonable interpretation (BRI), claim construction, estoppel, Innovation Act

Contacts

Jeffrey C. Totten
Partner
Washington, DC
+1 202 408 4232
Email

Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 

DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information. 

Related Insights

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Conference

NAPABA Convention 2026

November 12-14, 2026

Los Angeles

Conference

Broad's 3rd Annual Biotech IP Summit

November 10, 2026

Cambridge

Seminar

The Augmented Practice 2026: Balancing AI Opportunity, Governance, and Risk

November 5, 2026

San Francisco

Conference

IAM Live: Navigating the UPC 2026

November 4, 2026

Paris

Conference

2026 TIPA International Symposium

October 30, 2026

Taipei City

Conference

4th Global Patent Litigation FORUM

October 29, 2026

Munich

Conference

2026 AIPLA Annual Meeting

October 29-31, 2026

Washington, DC

Hybrid Conference

2026 Patent Law Institute: Critical Issues & Best Practices – New York

October 29, 2026

New York

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP